Metformin in Pregnancy: Mechanisms and Clinical Applications

Area of Science:

• Obstetrics and Gynecology
• Endocrinology
• Pharmacology

Background:

• Metformin use in pregnancy is rising globally due to increasing evidence of its safety and effectiveness.
• The Metformin in Gestational Diabetes (MiG) trial established metformin as a viable alternative to insulin for gestational diabetes, showing comparable outcomes with improved maternal weight management and acceptability.

Purpose of the Study:

• To review the evidence supporting metformin use in pregnancy, including its efficacy, safety, and long-term offspring outcomes.
• To discuss the mechanism of action of metformin and analyze key clinical trial data.

Main Methods:

• Review of randomized controlled trials (RCTs) and observational data on metformin use during pregnancy.
• Analysis of data from the Metformin in Gestational Diabetes (MiG) study, including long-term follow-up of offspring.

Main Results:

• Metformin demonstrates comparable pregnancy outcomes to insulin therapy in gestational diabetes, with benefits of reduced maternal weight gain and high patient acceptance.
• No increased risk of congenital malformations or miscarriages has been observed with metformin use in pregnancy.
• Long-term body composition and metabolic outcomes for offspring exposed to metformin in utero are being reported.

Conclusions:

• Metformin is a safe and effective treatment option for various conditions during pregnancy, including gestational diabetes, polycystic ovarian syndrome, and obesity.
• Continued research and clinical trials are evaluating metformin's role, including its combination with insulin for type 2 diabetes in pregnancy.
• Emerging data on long-term offspring health supports the established safety profile of metformin in pregnancy.